Citryll
Oss, NL · Founded 2015 · 6 known investors
Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa. The company runs clinical trials for its ET-targeting therapy aimed at resolving inflammation.
BiotechHealthtechMedical Devices
Investors · 6
In the news
Frequently asked questions
- What does Citryll do?
- Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa. The company runs clinical trials for its ET-targeting therapy aimed at resolving inflammation.
- Who are Citryll's investors?
- Citryll's investors include BOM, Curie Capital, Novartis Venture Fund, Pureos Bioventures, BioGeneration Ventures, Forbion.
- Where is Citryll headquartered?
- Citryll is headquartered in Oss, NL.